Liquidia sales accelerates 31% to $222.7 million

Liquidia (NASDAQ) reported third-quarter 2026 YUTREPIA net product sales of $222.7 million, up 31% from the previous quarter and compared with $51.7 million a year earlier.

The company recorded a net loss of $236.3 million, or $2.64 per share, compared with a $3.5 million loss in the prior-year quarter.

Results included a $389.7 million litigation settlement charge, while non-GAAP adjusted EBITDA increased for the fifth consecutive quarter to $140.5 million.

An October 13 settlement with United Therapeutics resolved all six pending lawsuits and preserved uninterrupted YUTREPIA availability, while requiring Liquidia to stop promoting its use for pulmonary hypertension associated with interstitial lung disease.

The agreement includes net payments of $380.7 million during 2026 and 2027, and Liquidia had $396.1 million in cash before settlement payments; following the announcement, the Liquidia share-price direction and trading price were not provided in the available results.

YUTREPIA received FDA Fast Track designation for systemic sclerosis-associated Raynaud's phenomenon, adding another development opportunity for the company's product portfolio.

Liquidia also enrolled the first patient in its Phase 2 RE-WARM study, while submitting a request to remove the pulmonary hypertension associated with interstitial lung disease indication.